Carillon Tower Advisers Inc. acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, HoldingsChannel reports. The firm acquired 248,386 shares of the company’s stock, valued at approximately $38,842,000.
Several other hedge funds also recently bought and sold shares of IDXX. Zions Bancorporation bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $162,000. Benjamin F. Edwards & Company Inc. increased its position in shares of IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after purchasing an additional 1,000 shares during the last quarter. SignalPoint Asset Management LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $200,000. Ledyard National Bank increased its position in shares of IDEXX Laboratories by 58.9% in the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after purchasing an additional 480 shares during the last quarter. Finally, BB&T Securities LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $213,000. Institutional investors own 86.02% of the company’s stock.
Several research analysts recently weighed in on IDXX shares. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Piper Jaffray Companies started coverage on shares of IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price objective on the stock. Canaccord Genuity restated a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a research report on Monday, January 29th. Finally, Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $194.00.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. IDEXX Laboratories’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.58 earnings per share. equities analysts expect that IDEXX Laboratories, Inc. will post 4.09 EPS for the current year.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total value of $2,972,700.00. Following the completion of the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at $177,885,046.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Giovani Twigge sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,762 shares of company stock valued at $15,940,404. 2.77% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3225010/carillon-tower-advisers-inc-invests-38-84-million-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.